Colorectal Cancer

DNA-based stool test more sensitive than fecal occult blood test in study

Published in Cancer Weekly, November 11th, 2003

Exact Sciences Corporation (EXAS) announced that its multi-center study of PreGen-Plus versus the fecal occult blood test (FOBT) achieved its primary endpoint of superiority with high statistical significance (p<.001).

The data was presented at a satellite symposium at the American College of Gastroenterology 2003 Annual Conference. PreGen-Plus, Exact Sciences' DNA-based stool test, was four times more sensitive than the most widely used fecal occult blood test (Hemoccult II) for the detection of colon cancer in an average-risk, asymptomatic population.

Data in the population studied indicated a point sensitivity for FOBT of 13% and a point...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-11-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry